Boston Scientific Reports Strong Q3 Growth Fueled by Cardiovascular Segment Success
- Boston Scientific reports Q3 2025 net sales of $5.065 billion, up 20.3% from last year.
- The Cardiovascular segment leads growth with a 22.4% increase, while the US market surges 27%.
- Regulatory approval for FARAPULSE™ positions Boston Scientific for continued growth and innovation in medical devices.
Boston Scientific Achieves Strong Q3 Performance Driven by Cardiovascular Growth
Boston Scientific Corporation reports robust financial results for the third quarter of 2025, marking a pivotal moment for the company in the medical device industry. The company achieves net sales of $5.065 billion, reflecting a substantial increase of 20.3% on a reported basis, 19.4% operationally, and 15.3% organically compared to the same period last year. The net income attributable to common stockholders also shows impressive growth, rising to $755 million, or $0.51 per share, up from $469 million, or $0.32 per share, in the previous year. CEO Mike Mahoney attributes this success to the commitment of the global team and a steadfast focus on innovation and category leadership.
A closer look at the sales reveals that the Cardiovascular segment is the standout performer, with a remarkable 22.4% increase on a reported basis. The MedSurg segment also contributes positively with a 16.4% growth. Regional performance highlights the United States as a key market, experiencing a 27% surge, while growth in Europe, the Middle East, and Africa remains slower at 2.6%. Other regions, such as Asia-Pacific and Latin America, also show promising growth rates of 17.1% and 10.4%, respectively. Despite the overall positive results, Boston Scientific makes a strategic decision to discontinue sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems, previously generating around $50 million in quarterly revenue. This move indicates a shift in focus towards more promising product lines.
In addition to the impressive financial results, Boston Scientific announces an important regulatory milestone with the approval from Japan’s Pharmaceuticals and Medical Device Agency (PMDA) for expanded labeling of the FARAPULSE™ Pulsed Field Ablation System. This strategic enhancement of product offerings positions Boston Scientific favorably within the competitive landscape of the medical device sector. The combination of strong quarterly performance and regulatory advancements not only highlights Boston Scientific's commitment to innovation but also reinforces its potential for continued growth in the evolving healthcare market.
Broader Implications in the Medical Device Sector
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

